- Home
- ACON vs TOVX Comparison
ACON vs TOVX Comparison
Compare ACON & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- TOVX
- Stock Information
- Founded
- ACON 2008
- TOVX 2001
- Country
- ACON United States
- TOVX United States
- Employees
- ACON N/A
- TOVX N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- TOVX Health Care
- Exchange
- ACON Nasdaq
- TOVX Nasdaq
- Market Cap
- ACON 4.8M
- TOVX 4.0M
- IPO Year
- ACON 2022
- TOVX 2006
- Fundamental
- Price
- ACON $7.64
- TOVX $1.41
- Analyst Decision
- ACON Buy
- TOVX Strong Buy
- Analyst Count
- ACON 2
- TOVX 1
- Target Price
- ACON $481.00
- TOVX $6.00
- AVG Volume (30 Days)
- ACON 75.1K
- TOVX 21.6K
- Earning Date
- ACON 04-09-2025
- TOVX 05-06-2025
- Dividend Yield
- ACON N/A
- TOVX N/A
- EPS Growth
- ACON N/A
- TOVX N/A
- EPS
- ACON N/A
- TOVX N/A
- Revenue
- ACON $45,724.00
- TOVX N/A
- Revenue This Year
- ACON $251.35
- TOVX N/A
- Revenue Next Year
- ACON N/A
- TOVX N/A
- P/E Ratio
- ACON N/A
- TOVX N/A
- Revenue Growth
- ACON N/A
- TOVX N/A
- 52 Week Low
- ACON $7.26
- TOVX $0.96
- 52 Week High
- ACON $6,241.05
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- ACON 33.40
- TOVX 58.99
- Support Level
- ACON $8.15
- TOVX $1.28
- Resistance Level
- ACON $8.30
- TOVX $1.47
- Average True Range (ATR)
- ACON 1.25
- TOVX 0.13
- MACD
- ACON 6.41
- TOVX 0.03
- Stochastic Oscillator
- ACON 6.94
- TOVX 87.13
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.